Christophe Arbet-Engels sold $5,284 of XFOR
Chief Medical Officer at X4 Pharmaceuticals, Inc. 11,624 shares at an average of $0.45, traded Jan 24, 2025, filed Jan 27, 2025.
Score components
- +15RoleOfficer
- 0Trade size$5k at market
- +10Share of holdings soldSold 45% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.3%, 3m -63.9%, 6m -85.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-002705, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 23, 2025 | AGrant or award Common Stock | +25,831 | $0.00 | $0 | 25,831 | Jan 27, 2025 |
| Jan 24, 2025 | SOpen-market sale Common Stock10b5-1 | -11,624 | $0.45 | $5,284 | 14,207 | Jan 27, 2025 |
Related signals
Other insiders at X4 Pharmaceuticals, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | XFORsell X4 Pharmaceuticals, Inc | David Kirske Chief Financial Officer | $34k 11,767 shares | -7% | |
| 30Weak | XFORsell X4 Pharmaceuticals, Inc | David Kirske Chief Financial Officer | $73k 16,961 shares | -9% | |
| 47Moderate | XFORbuy X4 Pharmaceuticals, Inc | Adam R Craig Executive Chairman | $250k 86,206 shares | +30% | |
| 33Weak | XFORbuy X4 Pharmaceuticals, Inc | Mark Baldry Chief Commercial Officer | $2,561 1,032 shares | +4% | |
| 21Weak | XFORbuy X4 Pharmaceuticals, Inc | Mark Baldry Chief Commercial Officer | $19k 35,050 shares | +37% | |
| 15Weak | X4 Pharmaceuticals, Inc | Mark Baldry Chief Commercial Officer | $13k 29,159 shares | -24% | |
| 15Weak | X4 Pharmaceuticals, Inc | Mary DiBiase Chief Operating Officer | $10k 22,258 shares | -4% | |
| 5Weak | X4 Pharmaceuticals, Inc | Paula Ragan President and CEO | $13k 31,897 shares | -3% | |
| 5Weak | X4 Pharmaceuticals, Inc | Paula Ragan President and CEO | $18k 31,897 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.